JP2018508475A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508475A5 JP2018508475A5 JP2017536240A JP2017536240A JP2018508475A5 JP 2018508475 A5 JP2018508475 A5 JP 2018508475A5 JP 2017536240 A JP2017536240 A JP 2017536240A JP 2017536240 A JP2017536240 A JP 2017536240A JP 2018508475 A5 JP2018508475 A5 JP 2018508475A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- binding
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 87
- 102000036639 antigens Human genes 0.000 claims description 87
- 108091007433 antigens Proteins 0.000 claims description 87
- 239000012634 fragment Substances 0.000 claims description 86
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 33
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 33
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 19
- 238000000338 in vitro Methods 0.000 claims description 15
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 9
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 230000004064 dysfunction Effects 0.000 claims description 7
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- -1 ICOS Proteins 0.000 claims description 6
- 241001529936 Murinae Species 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 4
- 230000003915 cell function Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
- 102100021501 ATP-binding cassette sub-family B member 5 Human genes 0.000 claims description 2
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 102100038078 CD276 antigen Human genes 0.000 claims description 2
- 101710185679 CD276 antigen Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102100032912 CD44 antigen Human genes 0.000 claims description 2
- 108010065524 CD52 Antigen Proteins 0.000 claims description 2
- 102000024905 CD99 Human genes 0.000 claims description 2
- 108060001253 CD99 Proteins 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
- 101000677872 Homo sapiens ATP-binding cassette sub-family B member 5 Proteins 0.000 claims description 2
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 claims description 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 2
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 2
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 claims description 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 2
- 102000002698 KIR Receptors Human genes 0.000 claims description 2
- 108010043610 KIR Receptors Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 102100023123 Mucin-16 Human genes 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 2
- 102100040120 Prominin-1 Human genes 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 2
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 claims description 2
- 230000017274 T cell anergy Effects 0.000 claims description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 2
- 102000048776 human CD274 Human genes 0.000 claims description 2
- 102000048362 human PDCD1 Human genes 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 description 24
- 102000004196 processed proteins & peptides Human genes 0.000 description 24
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1500319.7A GB201500319D0 (en) | 2015-01-09 | 2015-01-09 | Anti-PD-L1 antibodies |
| GB1500319.7 | 2015-01-09 | ||
| PCT/SG2016/050001 WO2016111645A1 (en) | 2015-01-09 | 2016-01-04 | Anti-pd-l1 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508475A JP2018508475A (ja) | 2018-03-29 |
| JP2018508475A5 true JP2018508475A5 (OSRAM) | 2019-02-14 |
| JP6866294B2 JP6866294B2 (ja) | 2021-04-28 |
Family
ID=52597403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017536240A Active JP6866294B2 (ja) | 2015-01-09 | 2016-01-04 | 抗ｐｄ−ｌ１抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10517949B2 (OSRAM) |
| EP (1) | EP3242894B1 (OSRAM) |
| JP (1) | JP6866294B2 (OSRAM) |
| KR (1) | KR102713223B1 (OSRAM) |
| CN (1) | CN107428832B (OSRAM) |
| AU (1) | AU2016205518B2 (OSRAM) |
| CA (1) | CA2973332C (OSRAM) |
| ES (1) | ES2835869T3 (OSRAM) |
| GB (1) | GB201500319D0 (OSRAM) |
| SG (1) | SG11201705552QA (OSRAM) |
| WO (1) | WO2016111645A1 (OSRAM) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012026227A2 (pt) | 2010-04-13 | 2020-08-04 | Celldex Therapeutics, Inc. | anticorpo monoclonal humano ou humanizado, molécula biespecífica, vetor de expressão, célula transformada, composição, e, usos de um anticorpo |
| MD20180107A2 (ro) | 2013-03-18 | 2019-06-30 | Biocerox Products B.V. | Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora |
| PL3081576T3 (pl) | 2013-12-12 | 2020-03-31 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| TW202132337A (zh) | 2014-05-28 | 2021-09-01 | 美商艾吉納斯公司 | 抗糖皮質素誘導性ｔｎｆｒ家族相關性受體（ｇｉｔｒ）抗體類及使用彼等之方法 |
| GB201500319D0 (en) * | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| WO2016149201A2 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| EP3383430A4 (en) | 2015-12-02 | 2019-12-18 | Agenus Inc. | ANTIBODIES AND METHOD FOR USE THEREOF |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| SG11201811184UA (en) | 2016-06-20 | 2019-01-30 | F Star Beta Ltd | Lag -3 binding members |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| AU2017305366B2 (en) * | 2016-08-04 | 2019-06-20 | Innovent Biologics (Suzhou) Co., Ltd | Anti-PD-L1 nanobody and use thereof |
| JP7198752B2 (ja) | 2016-08-09 | 2023-01-04 | カイマブ・リミテッド | 抗ｉｃｏｓ抗体 |
| US11317611B2 (en) | 2016-08-31 | 2022-05-03 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric PD-L1 |
| CN107773762B (zh) * | 2016-08-31 | 2021-06-15 | 上海干云生物科技有限公司 | 基于pd-l1抗体偶联化疗药物的adc及其制备方法和应用 |
| CN107815466B (zh) | 2016-08-31 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| UA127449C2 (uk) | 2016-09-23 | 2023-08-30 | Мерус Н.В. | Зв'язувальна молекула, яка модулює біологічну активність, що експресується клітиною |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| WO2018089628A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| US11958913B2 (en) * | 2017-01-09 | 2024-04-16 | Biomunex Pharmaceuticals | Polypeptide linker for preparing multispecific antibodies |
| BR112019017628A2 (pt) | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição |
| WO2018183842A1 (en) | 2017-03-31 | 2018-10-04 | The Board Of Trustees Of The Leland Standford Junior University | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
| IL269970B (en) | 2017-04-14 | 2022-09-01 | Tallac Therapeutics Inc | Polynucleotides that modulate the immune system, their antibody binding, and methods of using them |
| RU2665790C1 (ru) | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело к pd-l1 |
| SG11201909749PA (en) | 2017-04-21 | 2019-11-28 | Baylor College Medicine | Oncolytic virotherapy and immunotherapy |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| CN110799546B (zh) * | 2017-09-01 | 2023-01-24 | 四川科伦博泰生物医药股份有限公司 | 重组双特异性抗体 |
| WO2019075097A1 (en) | 2017-10-11 | 2019-04-18 | Board Of Regents, The University Of Texas System | PD-L1 HUMAN ANTIBODIES AND METHODS OF USE |
| WO2019083971A1 (en) | 2017-10-23 | 2019-05-02 | Children's Medical Center Corporation | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY |
| CN111954680B (zh) | 2017-11-10 | 2024-03-15 | 新加坡科技研究局 | IL2Rβ/共同γ链抗体 |
| US11306119B2 (en) | 2017-12-15 | 2022-04-19 | Kyungpook National University Industry-Academic Cooperation Foundation | Peptide bound to PD-L1 and use thereof |
| KR102150419B1 (ko) * | 2017-12-15 | 2020-09-01 | 경북대학교 산학협력단 | Pd-l1에 결합하는 펩타이드 및 이의 용도 |
| US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| WO2019121906A1 (en) * | 2017-12-19 | 2019-06-27 | F-Star Beta Limited | Specific pd-l1 binding sequences inserted in a ch3 domain |
| CN109970857B (zh) * | 2017-12-27 | 2022-09-30 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
| KR102311838B1 (ko) * | 2017-12-27 | 2021-10-14 | 주식회사 파멥신 | 항-pd-l1 항체 및 이의 용도 |
| EP3740756A4 (en) * | 2018-01-15 | 2021-10-27 | Epiaxis Therapeutics Pty Ltd | AGENTS AND METHODS FOR PREDICTING THE THERAPEUTIC RESPONSE |
| EP3768726B1 (en) | 2018-03-23 | 2024-10-30 | Board of Regents, The University of Texas System | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor |
| WO2019182867A1 (en) | 2018-03-23 | 2019-09-26 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor |
| JP7390301B2 (ja) | 2018-03-23 | 2023-12-01 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ヒトｐｄ－ｌ２抗体およびその使用方法 |
| US12054556B2 (en) | 2018-04-09 | 2024-08-06 | Oricell Therapeutics Co., Ltd. | Anti-PD-L1 antibody and use thereof |
| SG11202009791VA (en) * | 2018-04-09 | 2020-11-27 | Origincell Therapeutics Co Ltd | Anti-pd-l1 antibody and use thereof |
| JP2021521778A (ja) * | 2018-04-16 | 2021-08-30 | メモリアル スローン ケタリング キャンサー センター | Ｔ細胞枯渇、およびそれに関連する方法および組成物 |
| CN112292185B (zh) | 2018-04-17 | 2025-07-29 | 塞德斯医疗公司 | 抗cd27和抗pd-l1抗体及双特异性构建体 |
| MX2020011588A (es) * | 2018-05-03 | 2020-12-07 | Shanghai Epimab Biotherapeutics Co Ltd | Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas. |
| EP3796977A4 (en) * | 2018-05-17 | 2022-03-02 | The Board of Trustees of the Leland Stanford Junior University | RECEPTOR INHIBITION BY PHOSPHATASE RECRUITMENT |
| MX2021000399A (es) | 2018-07-12 | 2021-05-27 | F Star Therapeutics Ltd | Moleculas de anticuerpo que se unen a cd137 y ox40. |
| AU2019301204B2 (en) | 2018-07-12 | 2025-10-23 | Invox Pharma Limited | Antibody molecules that bind PD-L1 and CD137 |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811403D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| CN112955221A (zh) | 2018-08-27 | 2021-06-11 | 皮里斯制药有限公司 | 包含cd137/her2双特异性试剂和pd-1轴抑制剂的组合疗法及其用途 |
| KR20210091714A (ko) * | 2018-10-17 | 2021-07-22 | 이뮤놈 인코포레이티드 | 엑소좀-표적 이중 특이적 항체 |
| TWI856035B (zh) | 2018-10-25 | 2024-09-21 | 貝勒醫學院 | 溶瘤病毒療法及免疫療法 |
| WO2020094834A1 (en) | 2018-11-09 | 2020-05-14 | Euchloe Bio Pte. Ltd. | Il2rbeta/common gamma chain antibodies |
| TW202039557A (zh) | 2018-11-09 | 2020-11-01 | 新加坡商優其洛伊生物私人有限公司 | 介白素2受體β(IL2Rβ)/共同γ鏈抗體 |
| US11046769B2 (en) * | 2018-11-13 | 2021-06-29 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
| SG11202106768RA (en) * | 2018-12-27 | 2021-07-29 | Gigagen Inc | Anti-pd-l1 binding proteins and methods of use thereof |
| JP7695698B2 (ja) * | 2019-01-14 | 2025-06-19 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 細胞内部移行をモジュレートするための組成物および方法 |
| WO2020150282A1 (en) * | 2019-01-18 | 2020-07-23 | Askgene Pharma Inc. | Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis |
| TWI793395B (zh) * | 2019-01-25 | 2023-02-21 | 大陸商信達生物製藥（蘇州）有限公司 | 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體 |
| US12331120B2 (en) | 2019-04-11 | 2025-06-17 | Scripps Korea Antibody Institute | Antibodies against programmed death-ligand 1 and uses thereof |
| EP3972998A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Cd19 binding molecules and uses thereof |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| US20220332827A1 (en) * | 2019-08-23 | 2022-10-20 | WuXi Biologics Ireland Limited | Humanized antibodies against pd-l1 |
| WO2021097800A1 (en) * | 2019-11-22 | 2021-05-27 | Abl Bio Inc. | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof |
| US11920136B2 (en) | 2020-02-28 | 2024-03-05 | Tallac Therapeutics, Inc. | Transglutaminase-mediated conjugation |
| KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
| WO2022040482A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| EP4242232A4 (en) * | 2020-11-06 | 2024-09-11 | Bio-Thera Solutions, Ltd. | BISPECIFIC ANTIBODY AND ITS USE |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
| WO2022243378A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| AU2022312698A1 (en) | 2021-07-13 | 2024-01-25 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| CN114478789B (zh) * | 2021-12-20 | 2024-06-14 | 安徽安科生物工程（集团）股份有限公司 | 抗pd-l1与ox40双特异性抗体及其用途 |
| CN114470195A (zh) * | 2022-01-19 | 2022-05-13 | 同济大学 | 一种抗真菌制剂、抑制细胞pd-l1表达的抑制剂及应用 |
| MX2024010339A (es) | 2022-02-23 | 2024-09-30 | Xencor Inc | Anticuerpos anti-cd28 x anti-psma. |
| US20250340641A1 (en) | 2022-05-18 | 2025-11-06 | Kymab Limited | Uses of anti-icos antibodies |
| AU2023401158A1 (en) | 2022-12-01 | 2025-05-29 | BioNTech SE | Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy |
| CN120418289A (zh) | 2022-12-14 | 2025-08-01 | 安斯泰来制药欧洲有限公司 | 结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法 |
| IL321997A (en) * | 2023-01-10 | 2025-09-01 | Sana Biotechnology Inc | CD19-specific antibody structures and preparations thereof |
| CN120813375A (zh) | 2023-01-30 | 2025-10-17 | 凯玛布有限公司 | 抗体 |
| US12319747B2 (en) | 2023-07-03 | 2025-06-03 | Medicovestor, Inc. | Methods of using anti-SP17 immunotherapeutics |
| US20250011420A1 (en) * | 2023-07-03 | 2025-01-09 | Medicovestor, Inc. | Proteins that bind sp17 including fully-human anti-sp17 antibodies |
| WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
| US12364777B2 (en) * | 2023-10-20 | 2025-07-22 | Medicovestor, Inc. | Homodimeric antibodies for use in treating cancers and methods of use |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| US12116410B1 (en) | 2023-12-26 | 2024-10-15 | Medicovestor, Inc. | Methods of manufacturing dimeric antibodies |
| CN120305419B (zh) * | 2025-06-17 | 2025-11-21 | 中国医学科学院医药生物技术研究所 | 一种pd-l1靶向性仿生外泌体和包含其的药物组合物及应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US98415A (en) * | 1869-12-28 | Improved folding chair | ||
| EP1537878B1 (en) * | 2002-07-03 | 2010-09-22 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions |
| PL3428191T3 (pl) * | 2004-10-06 | 2025-04-07 | Mayo Foundation For Medical Education And Research | B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego |
| EP2418278A3 (en) * | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| DK1907000T4 (da) | 2005-06-08 | 2020-03-30 | The President And Fellows Of Harvard College | Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1). |
| KR101607288B1 (ko) * | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| TWI729512B (zh) * | 2008-12-09 | 2021-06-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| EP3192811A1 (en) * | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| CN104961829B (zh) * | 2009-11-24 | 2018-08-21 | 米迪缪尼有限公司 | 针对b7-h1的靶向结合剂 |
| US20140065035A1 (en) * | 2011-04-19 | 2014-03-06 | Bio Focus Co., Ltd. | Method for manufacturing a microvalve device mounted on a lab-on-a-chip, and microvalve device manufactured by same |
| KR101981873B1 (ko) * | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| KR102702287B1 (ko) | 2012-05-15 | 2024-09-04 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
| KR102410078B1 (ko) * | 2012-05-31 | 2022-06-22 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| WO2014055897A2 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| LT3212670T (lt) | 2014-10-29 | 2021-02-10 | Five Prime Therapeutics, Inc. | Kombinuotasis vėžio gydymas |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| SG11201909749PA (en) * | 2017-04-21 | 2019-11-28 | Baylor College Medicine | Oncolytic virotherapy and immunotherapy |
| WO2021091560A1 (en) * | 2019-11-07 | 2021-05-14 | Baylor College Of Medicine | Oncolytic virotherapy and immunotherapy |
| CN115917316B (zh) * | 2020-06-12 | 2025-10-24 | 新加坡科技研究局 | 嗜中性粒细胞祖细胞及相关方法和用途 |
-
2015
- 2015-01-09 GB GBGB1500319.7A patent/GB201500319D0/en not_active Ceased
-
2016
- 2016-01-04 US US15/542,023 patent/US10517949B2/en active Active
- 2016-01-04 SG SG11201705552QA patent/SG11201705552QA/en unknown
- 2016-01-04 WO PCT/SG2016/050001 patent/WO2016111645A1/en not_active Ceased
- 2016-01-04 EP EP16735235.0A patent/EP3242894B1/en active Active
- 2016-01-04 CN CN201680014808.2A patent/CN107428832B/zh active Active
- 2016-01-04 CA CA2973332A patent/CA2973332C/en active Active
- 2016-01-04 AU AU2016205518A patent/AU2016205518B2/en active Active
- 2016-01-04 ES ES16735235T patent/ES2835869T3/es active Active
- 2016-01-04 KR KR1020177021198A patent/KR102713223B1/ko active Active
- 2016-01-04 JP JP2017536240A patent/JP6866294B2/ja active Active
-
2017
- 2017-06-15 US US15/623,679 patent/US9789183B1/en active Active
-
2019
- 2019-10-09 US US16/597,586 patent/US11534489B2/en active Active
-
2022
- 2022-11-23 US US18/058,699 patent/US12472252B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508475A5 (OSRAM) | ||
| JP2019519208A5 (OSRAM) | ||
| JP2018500924A5 (OSRAM) | ||
| JP2018527912A5 (OSRAM) | ||
| US11690908B2 (en) | Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy | |
| JP2017536111A5 (OSRAM) | ||
| RU2017116847A (ru) | Антитела к pd-1 | |
| JP6866294B2 (ja) | 抗ｐｄ−ｌ１抗体 | |
| JP2017538441A5 (OSRAM) | ||
| AU2016265845B2 (en) | Chimeric antigen receptor compositions | |
| JP7038353B2 (ja) | エクスビボのｂｉｔｅ活性化ｔ細胞 | |
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| US20230227553A1 (en) | Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof | |
| JP2019517773A (ja) | 抗ｌａｇ−３抗体 | |
| CN111246882A (zh) | 抗il1rap抗体 | |
| JP2020530989A5 (OSRAM) | ||
| FI3250592T3 (fi) | Transtyretiinin vastaisia vasta-aineita | |
| JP2019519208A (ja) | 抗ｃｔｌａ−４抗体 | |
| RU2015129551A (ru) | Антитела к в7-н4 человека и их применение | |
| JP2017510251A (ja) | 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体 | |
| JP2018508215A5 (OSRAM) | ||
| CN112955179A (zh) | 拮抗性抗肿瘤坏死因子受体超家族多肽 | |
| JP2018505681A5 (OSRAM) | ||
| CN114423497A (zh) | 修饰的细胞毒性t细胞及其使用方法 | |
| JP2014515600A5 (OSRAM) |